Looking for Adalimumab found 29 matches
|
| Open monograph to display formulary status |
BNF Category |
| |
Adalimumab
|
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
|
| |
Adalimumab
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Adalimumab
|
Eye - Other anti-inflammatory preparations - 11.04.02
|
| |
Adalimumab
|
Skin - Drugs affecting the immune response - 13.05.03
|
| |
Tocilizumab
(RoActemra®)
|
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
|
| |
Links Link to Drug Section  Link to document |
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
|
|
Adalimumab and Infliximab for Children with Severe Refractory Uveitis (11.04.02)
|
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis (13.05.03)
|
|
NICE TA187: Crohn’s disease - infliximab and adalimumab (01.05.03)
|
|
NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
|
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
|
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)
|
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)
|
|
NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.02)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
|
|
|
